Mark Foley: Sure. So €“ absolutely. Yes, we tried to cover some of that in our prepared comments. So with our PDUFA date in August this year, our hope is that we’ll get approved on our PDUFA date and we will launch something very similar to the PrevU program that we’ve done with RHA and with DAXXIFY. All with this goal of trying to really figure out what’s going to be the best way to drive depth and penetration. And this will give us an opportunity to engage with payers. It’ll give us an opportunity to get a lot of real world clinical use. Obviously, there’s a compelling value proposition to be made with a longer lasting toxin in these debilitating conditions. And we think this collective body of information will help inform our €“ the details of our go-to-market strategy and probably more importantly, even our pipeline strategy in terms of what other trials do we invest in from an indication expansion.
And so we’ll learn a lot through our PrevU phase later this year assuming approval, and then we’ll use that to inform our 2024 commercial launch strategy.
Annabel Samimy: Got it. Thank you.
Operator: Seamus Fernandez with Guggenheim Securities. Your line is open.
Seamus Fernandez: Great. Thanks so much, and sorry for the miss earlier. Just a couple of quick questions. I was just hoping that if you might, obviously, the consensus after the impressive fourth quarter uptake that I think really surprised relative to expectations, maybe it surprised you guys as well. But wanted to just get a sense, obviously consensus numbers have risen, what is your comfort with sort of the revenue range that sits out there today? I think given the initial uptake there definitely is a bias to get quite excited about that early launch trajectory. Just wanted to get a better sense of how to think about, I guess, as some would say, the rhythm of the numbers as we move through the balance of the year. And maybe if you could just provide a little context on the importance of Aji really coming online and the timing of Aji coming online to the contribution to the revenue potential for DAXI this year.
Mark Foley: Yes. Thanks, Seamus. It’s hard obviously to give guidance at this point, we’re €“ what two-quarter or two months into our PrevU launch, and so it’s very early. But there’s nothing that we’ve seen in the PrevU launch strategy that changes our optimism for the opportunity going forward or our strategy. And if we kind of take a step back when we look at it, we’ve talked about the fact that we think with the collection of assets that we have and the aesthetics franchise between our RHA, DAXXIFY and services segment that we can get to $1 billion of revenue in the U.S. aesthetics market. So we feel very good about where we are in that journey. It’s just €“ it’s hard to give any guidance right now given that we are so early in this journey.
What I will tell you is that we have a significant number of accounts who are very interested in getting trained and getting onboarded with DAXXIFY. We know that they have €“ within those practices a number of consumers who are very interested in getting DAXXIFY treatment. And that’s before, we’ve really amplified the awareness that’s out there. So we feel like we’re very well positioned in the PrevU program. We’ve been encouraged by the learnings that we’ve had and the experience that we’ve seen from both the injectors and from the consumers. I just think it’s a little early for us to give any commentary about how we feel about guidance given where we are in that phase. On the Aji side, we’ve long talked about what our supply chain strategy is.
